{
  "outcomes_metadata": {
    "timestamp": "2025-10-02T13:10:59.509931",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "consolidation_type": "outcomes",
    "data_split": "test",
    "total_unique_outcomes": 44,
    "source_countries": [
      "DE",
      "DK",
      "EN",
      "EU",
      "FR",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        "overall survival (OS)",
        "overall survival (time from randomisation to death from any cause)",
        "overall survival (time from randomization to death from any cause)",
        "overall survival",
        "prolonged survival",
        "progression-free survival (PFS)",
        "progression-free survival (blinded independent central review)",
        "progression-free survival (RECIST v1.1)",
        "progression-free survival (PFS; RECIST 1.1)",
        "progression-free survival (independent review committee, RECIST 1.1)",
        "progression-free survival",
        "event-free survival"
      ],
      "response_measures": [
        "objective response rate (ORR)",
        "objective response rate (independent review committee, RECIST 1.1)",
        "objective response rate (RECIST 1.1)",
        "overall response rate (ORR)",
        "overall response rate",
        "response rates",
        "disease control rate (complete, partial, or stable disease for â‰¥5 weeks)",
        "disease control rate",
        "time to response (from treatment initiation to first complete or partial response)",
        "time to response",
        "duration of response (DoR)",
        "duration of response (RECIST 1.1)",
        "duration of response"
      ],
      "progression_measures": [
        "time to progression (TTP)",
        "time to progression",
        "time to next treatment (TTNT)",
        "time to next treatment",
        "treatment duration",
        "duration of treatment"
      ]
    },
    "safety": {
      "adverse_events": [
        "adverse events",
        "adverse events (CTCAE v5.0)",
        "adverse events (CTCAE v4.03)",
        "adverse drug reactions",
        "side effects",
        "serious adverse events",
        "serious adverse events (Grade 3-4)",
        "serious undesirable effects",
        "mortality-related toxicity",
        "serious side effects on the skin",
        "diarrhoea",
        "alanine aminotransferase increase",
        "aspartate aminotransferase increase",
        "neutropenia",
        "fatigue",
        "febrile neutropenia"
      ],
      "serious_events": [
        "serious adverse events",
        "serious adverse events (Grade 3-4)",
        "serious undesirable effects",
        "mortality-related toxicity",
        "serious side effects on the skin"
      ],
      "discontinuations": [
        "treatment discontinuation due to adverse events (CTCAE v5.0)",
        "treatment discontinuation due to adverse events (CTCAE v4.03)",
        "dropout rate"
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        "EORTC QLQ-C30",
        "EORTC QLQ-LC13",
        "BPI-SF",
        "FACT-G GP5",
        "PGI-C",
        "EQ-5D-5L",
        "visual analogue scale (progression-free health state)"
      ],
      "functional_status": [
        "Karnofsky performance status",
        "ECOG performance status",
        "physical functioning"
      ],
      "symptom_measures": [
        "symptomatology",
        "symptom control",
        "preservation of quality of life",
        "health status",
        "health-related quality of life",
        "health-related quality of life (measured by time to death)",
        "overall health status",
        "quality of life"
      ]
    },
    "economic": {
      "cost_effectiveness": [
        "cost-effectiveness (incremental cost-effectiveness ratio, ICER)",
        "cost-effectiveness (cost per QALY)"
      ],
      "utilities": [
        "quality-adjusted life years (QALYs)",
        "utility decrement per cycle of treatment"
      ],
      "resource_utilization": []
    },
    "other": {
      "exploratory_endpoints": [],
      "biomarkers": []
    }
  }
}